Amgen (AMGN) Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
- U.S. Adds Jobs a Higher Clip in November, Unemployment Rate Falls to 7%
- Pre-Open Stock Movers 12/6: (ENZN) (GERN) (PSUN) Higher; (IOC) (ULTA) (PWRD) Lower (more...)
- Sears Holdings (SHLD) Files to Spin-Off Lands' End Unit
- Wow - Bitcoin 'is' the New Gold
- J.C. Penney (JCP) Discloses Letter from SEC on Liquidity, Cash, Debt and Stock Offering
Amgen (Nasdaq: AMGN) Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
You May Also Be Interested In
- The International Myeloma Foundation Announces Partnership With Onyx Pharmaceuticals to Support Black Swan Research Initiative(TM)
- RBCC Appoints New CEO to Achieve Regenerative Medicine Goals
- Joel Krasnow is Strong Hire for TherapeuticsMD - Analyst
Create E-mail Alert Related CategoriesFDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!